A complete application in a minute
Tailored resume and cover letter, ready to send.
Hawthorne Health is seeking an experienced Cardiology Principal Investigator (MD/DO) for a part-time, 1099 contract. The role leads Cardiology/Metabolic trials within a growing community-based site network and requires prior PI or Sub-I experience on sponsor-initiated trials.
On-site presence is needed 1–4 times per month with remote oversight, and compensation ranges from $100 to $250 per hour. Candidates must hold an unrestricted medical license; board certification in Cardiology is preferred.
Hawthorne Health is a leading community site network and home research visit solution provider, with 20+ sites and more than 2,000 research experienced healthcare professionals across the U.S. Hawthorne leverages convenient, trusted, healthcare locations, identified patient data, and intelligent technology to accelerate patient access, improve retention, and reduce study costs. By embedding high-quality research within local communities, Hawthorne makes clinical trials more accessible and convenient for patients. Our community-based model shortens timelines and helps bring better treatments to market, faster.
Hawthorne Health is seeking an experienced Cardiology Principal investigator (MD/DO) for a part-time, 1099 role. Candidates should have prior experience as a PI or Sub-I on sponsor-initiated clinical trials. This role will lead Cardiology/Metabolic trials within our growing, community-based site network—built to make research efficient, patient-friendly, and investigator-supported.
$100 - $250 an hour
This is a 1099 independent contractor opportunity. Compensation may be flexible and adjusted based on experience and qualifications.
Hawthorne Health is transforming the clinical trial landscape through an innovative site model that integrates research into community-based settings like local pharmacies. By meeting patients where they already receive care, we are improving access, strengthening trust, and driving more inclusive and efficient trials.
We welcome the opportunity to connect with individuals interested in being part of this evolving model.